Reddy’s Gets Six-Month Head Start On Carboprost In US
Dr Reddy’s will be alone in the US market for six months with the first generic rival to Pfizer’s Hemabate carboprost brand.
You may also be interested in...
After receiving a CGT designation by the FDA for its generic version of Amicar, Amneal gets 180 days of exclusivity.
With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.
As firms including Laurus Labs, Natco and Strides get GMP compliance nods, the FDA has pulled up Dr Reddy’s for GMP compliance issues. Meanwhile, Numaferm has struck a licensing deal and Olon has started constructing a new plant.